TABLE 3.
Baseline characteristics and outcomes of included patients, totals
| Parameters | Value |
|---|---|
| No. of patients studied | 53 |
| Age (year), mean ± SD | 25.3 ± 12.7 |
| First presentation, yes | 50 (94.3%) |
| History of CML, yes | 2 (3.8%) |
| Average duration of symptoms (days), median (Q1–Q3) (missing 11%) | 2 (0.58–4.0) |
| WBC count, ×109/L (mean ± SD) | 344 ± 147 |
| Platelet count, ×109/L, yes (missing 19%) | |
| <150 | 5 (9.4%) |
| 150–450 | 23 (43.4%) |
| >450 | 15 (28%) |
| Treatment received | |
| Combined | 36 (67.9%) |
| Unknown timeline/simultaneously | 7 (13.2%) |
| First urological | 26 (49.1%) |
| First oncological | 3 (5.7%) |
| Radiation | 3 (5.7%) |
| Urological | |
| Penile aspiration ± (alpha adrenergic agonist) irrigation | 41 (77.4%) |
| Shunt (distal/proximal) | 14 (26.4%) |
| Oncological | |
| Hyperhydration + allopurinol, hydroxycarbamide | 43 (81.1%) |
| Chemotherapeutic methods (chemo, TKI) | 30 (56.6%) |
| Leukapheresis | 12 (22.6%) |
| Resolution, yes (missing 11%) | 45 (84.9%) |
| Erectile dysfunction, yes (missing 60%) | 8 (15.1%) |
Note: Numbers (% of total number patients) unless otherwise specified. Missing data when >10% is mentioned.
Abbreviations: CML, chronic myeloid leukemia; Q1, quartile 1; Q3, quartile 3; SD, standard deviation; TKI, tyrosin kinase inhibitor; WBC, white blood cells.